Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
+6.1%
$0.01
$0.00
$0.04
N/AN/A135,541 shs250,437 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.04
$0.05
$0.01
$0.10
N/AN/A14,877 shs101 shs
TRSBF
3SBio
$4.59
$3.26
$2.22
$4.74
N/AN/A1,657 shs50 shs
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
$0.26
$0.27
$0.22
$0.55
N/AN/A398 shsN/A
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00%0.00%+49.38%+53.16%+19.81%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00%-20.67%-37.41%-38.07%-13.90%
TRSBF
3SBio
0.00%+17.69%+39.09%+454.41%+498.28%
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
0.00%0.00%-7.52%-13.88%-53.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$665.45KN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/A0.00N/AN/AN/AN/A8/20/2025 (Estimated)
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
N/AN/A0.00N/AN/AN/AN/A8/26/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A
TRSBF
3SBio
N/A
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable
Zelira Therapeutics Limited stock logo
ZLDAF
Zelira Therapeutics
N/AN/AN/ANot Optionable

Recent News About These Companies

ZLDAF Zelira Therapeutics Limited
Pot stocks could be about to smoke the ASX

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.01 +0.00 (+6.14%)
As of 08/1/2025 02:41 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.04 0.00 (0.00%)
As of 08/1/2025

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

3SBio OTCMKTS:TRSBF

$4.59 0.00 (0.00%)
As of 08/1/2025

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Zelira Therapeutics stock logo

Zelira Therapeutics OTCMKTS:ZLDAF

$0.26 0.00 (0.00%)
As of 08/1/2025

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.